Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

137 courses of illness were studied to determine, for different age groups, the incidence of early symptoms such as headache, dizziness, sleep disturbances, asynchronism, photism and singing and other sounds in the ear. The significance of prodromic signs, including uncharacteristic ones, in the overall diagnostic interpretation of cerebro-vascular insultus is indicated.
 ...
PMID:[Frequency of different prodromal signs in cerebrovascular insult]. 12 77

The authors present their observations on treatment with Noveril of nocturnal enuresis in 49 children aged from 6 to 16 years. The drug is a derivative of dibenzodiazepine belonging to the group of thymoleptic agents with an action similar to that of imipramine. Noveril was given in doses from 20 to 100 mg daily during 3 to 9 weeks. In the final evaluation of the drug the frequency of enuresis before, during and after treatment was taken into account. In 25 cases an improvement was observed, usually in psychogenic nocturnal enuresis. Side effects included oral dryness, headaches and dizziness, and sleep disturbances observed in 4 cases. The tolerance of the drug was good. Noveril has a favourable effect in children with nocturnal enuresis, particularly of psychogenic origin.
 ...
PMID:[Treatment of enuresis with Noveril]. 24 45

To investigate whether the preservation of atrioventricular (AV) synchronization matters for quality-of-life during pacemaker treatment we assessed 17 consecutive patients with high degree AV block and preserved sinus node function in a double-blind, long-term crossover study. A questionnaire with regard to cardiovascular symptoms, sleep disturbances, cognitive functioning, physical ability, social interaction, emotional functioning, and self-perceived health was completed after 2 months of atrial synchronous (DDD) and rate modulated ventricular pacing (VVI,R), respectively. A significant improvement in shortness of breath, dizziness and palpitations as well as an improvement of cognitive functioning was observed during DDD pacing. Nine patients preferred the DDD mode and three the VVI,R mode. The remaining five patients did not express any preference. The preference for the DDD mode was explained by a significant reduction of cardiovascular symptoms and an improved self-perceived health, physical ability, and psychological well-being during DDD pacing. All differences in quality-of-life parameters between the two modes of pacing favored the DDD mode and no adverse effects of this mode were found. Thus, the maintenance of AV synchrony adds further symptomatic relief compared to rate increase alone. The results indicate that DDD pacing is the preferred mode of pacing in patients with high degree AV block and preserved sinus node function.
 ...
PMID:Quality-of-life in patients treated with atrioventricular synchronous pacing compared to rate modulated ventricular pacing: a long-term, double-blind, crossover study. 138 58

Health and environmental assessment of the consequences of accidental contamination of an area in the Negev desert is described and the effects of exposure to bromine vapor in 6 persons evaluated. They were only mildly affected during the acute spillage of the bromine, with some respiratory symptoms and first and second degree skin burns of small exposed areas on the legs. All were treated in hospital and were released within 1-4 days. 6-8 weeks later they demonstrated a complex array of complaints, including cough, shortness of breath, chest tightness, eye irritation, headache, dizziness, fatigue, memory disturbances, sleep and sexual disturbances. These complaints could not be substantiated by objective clinical or laboratory examination. There was thus obvious magnification of the complaints 1-2 months after the accident.
 ...
PMID:[Late health sequelae of accidental bromine exposure]. 225 10

In order to investigate the efficacy and safety of long-term treatment with flupirtine in patients with chronic pain, in particular arthrosis and arthritis, a study was planned which, when completed, will encompass the treatment of 200 patients over a 12-month period. The present paper is a preliminary report of this ongoing study. The report deals with 104 patients: 55 of whom completed the 12-month treatment period and a 2-week follow-up phase, during which flupirtine was replaced by placebo in order to be able to detect drug-withdrawal effects. Forty nine patients withdrew from the study. Most of the patients were suffering from degenerative rheumatic arthrosis or inflammatory rheumatic arthritis. The average daily dosage was 300 mg. The incidence of drop-outs was highest in the first months with hardly any patients withdrawing in the last six months. Fifteen patients dropped out because of side effects (dizziness, nausea, sleep disturbances, and headache). Ten patients dropped out because of ineffectiveness, seven because of side effects plus ineffectiveness, and three because of side effects and other reasons. The remaining 14 patients dropped out because of other or non-medical reasons. For the 55 patients who completed the study, the analgesic took effect within 45 minutes to 2 hours, the duration of effect was 4-6 hours. Three-quarters of the patients responded to the drug, one-quarter did not. The analgesic effect remained constant during the 12-month treatment, as did the average number of capsules taken per month. There was no evidence that tolerance developed. The most frequent side effects were drowsiness (9% of patients), dizziness (11%), dry mouth (5%) and pruritus (9%). The withdrawal symptom scale completed every month during treatment (to determine baseline values) and every day throughout the 2-week placebo post-treatment phase showed no changes in the median. The mean value increased during the withdrawal phase, however, indicating that the symptomatology was more pronounced in some subjects. After withdrawal, the non-specific symptoms increased to a greater extent than symptoms from the opiate scale. The symptoms were present throughout the withdrawal phase. If the withdrawal phenomena had corresponded to the flupirtine's terminal half-life, then the symptoms ought to have been present mainly in the first few days. There was a slight trend for lowering systolic blood pressure but no changes in diastolic blood pressure or heart rate, nor changes in the ECG or laboratory analysis that could be related to flupirtine. These preliminary data suggest that flupirtine is safe when given for a period of one year.
 ...
PMID:On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis. 245 18

203 patients with a diastolic blood pressure higher than 100 mmHg were included in a randomized, double-blind trial to compare the antihypertensive efficacy of different daily dosages of bopindolol (Wandonorm) (0.05 mg, 0.5 mg, 1 mg, 2 mg) and nifedipine (2 x 20 mg). After 4 weeks of therapy blood pressure normalization could be achieved in 23.7% (0.05 mg), 32.5% (0.5 mg), 67.5% (1 mg), 64.1% (2 mg) and 59.0% (nifedipine) of the patients, respectively. In a subgroup of 159 patients the study was continued with an 8-week dose titration and a 16-week observation. At the end of the study blood pressure normalization was achieved in 91% and 94% of the patients treated with nifedipine and bopindolol, respectively. Most patients of the bopindolol-group needed 1 mg once daily as compared to those on the nifedipine who required 20 mg b.i.d. Because of intolerable side effects therapy was discontinued in 3 out of 162 patients on bopindolol and in 3 out of 41 patients on nifedipine. As compared to nifedipine the tolerance of bopindolol was judged significantly superior because tiredness and dizziness (32% vs 9%) and leg edema (20% vs. 6%) were recorded much more frequently in nifedipine treated patients. In 135 elderly patients "quality of life" was assessed upon by use of the "Nuremberg-Alters-Selbstbeurteilungs-Skala" (NAS), which refers to social contacts, mental and physical performance, sleep disturbances and general well-being.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Beta receptor block versus calcium antagonism. A comparative study of bopindolol and nifedipine with special regard to quality of life]. 256 38

Behavioural therapy was given to reduce discomfort and annoyance associated with severe tinnitus in 75 consecutive patients. Treatment was conducted within the routine clinical management. It included information and discussion about tinnitus, behavioural analysis and relaxation training combined with various cognitive strategies. The method of treatment was thus a form of coping technique. Self-recordings showed significant reductions of 'discomfort from tinnitus' as well as significant elevations in 'general mood' over a 3-month follow-up period. Interview findings indicated strong overall positive effects of treatment, as well as other positive side-effects on complaints such as tension headaches, dizziness, muscle tension and sleep disturbances. Implications for the clinical management of tinnitus sufferers are discussed.
 ...
PMID:Behavioural therapy in the clinical management of tinnitus. 324 16

Fluoxetine, a selective serotonin uptake inhibitor (mean dose 73 mg each morning) was compared with amitriptyline (mean dose 122 mg at night) in a double-blind study of 64 depressed out-patients. Fifty patients completed the 6-week trial. The drugs did not differ with respect to psychiatrists' ratings, but amitriptyline was slightly superior with respect to patients' ratings. The amitriptyline-treated group had complaints of dry mouth and dizziness on standing; the fluoxetine-treated group of sleep disturbances, nausea, and headaches.
 ...
PMID:A controlled comparison of fluoxetine and amitriptyline in depressed out-patients. 332 68

This was an open-label study in 19 children aged 9-13 years, weighing 27-44 kg, with bronchial asthma. Twenty-four-hour steady-state concentrations of theophylline and its metabolites 1,3-dimethyl uric acid, 3-methyl xanthine and 1-methyl uric acid were assessed after daily dosing of 600 mg (ca 18 mg/kg/day) of the sustained-release theophylline micro-pellet sprinkle system BY158K, for 4 days. The dosing regimen used was an unequal twice-daily dose of 200 mg in the morning after breakfast and 400 mg in the evening after dinner. Twenty-four-hour peak expiratory flow (PEF) profiles were compared before treatment and at steady-state, along with lung function parameters after bronchial provocation. Mean values +/- SD (n = 16) of the steady-state characteristics were Cmin 6.8 +/- 2.1 mg/l, Cmax 14.5 +/- 4.8 mg/l and Cav 10.5 +/- 2.9 mg/l, the plateau time was 11.7 +/- 4.8 hr and peak-trough fluctuation and swing were 72 +/- 21 and 118 +/- 52%, respectively. There was an excellent reproducibility of theophylline pre-dose levels at corresponding time points of the 24-hr sampling period [r = 0.864 (p less than 0.001)]. Mean values +/- SD of the 24 hr average serum metabolite levels were 0.9 +/- 0.2 mg/1 for 1,3-dimethyl uric acid, 0.6 +/- 0.1 mg/1 for 3-methyl xanthine and 0.4 +/- 0.1 mg/1 for l-methyl uric acid. Lung function (n = 17) following bronchial provocation, improved in 10 children after theophylline treatment of 4 days, remained stable in 2 patients and deteriorated in 5 patients. Serum theophylline profiles and PEF profiles ran largely in parallel over the 24-hr period. Six children exhibited typical theophylline induced side-effects, headache (n = 3), nausea (n = 4), dizziness (n = 1), vomiting (n = 4), sleep disturbances (n = 1), pallor (n = 1) and tremor (n = 1), necessitating in 3 children one dose omission/reduction (n = 2) or subsequent dose reduction (n = 1). It has been shown that a twice daily dosing regimen with unequal doses of anhydrous theophylline (BY158K) is well suited to this population of fast metabolisers. The patients were well protected throughout the day, including the critical early morning hours.
 ...
PMID:Steady state pharmacokinetics, metabolism and pharmacodynamics of theophylline in children after unequal twice-daily dosing of a new sustained-release formulation. 367 17

The action of bromazepam was assessed in 30 patients whose dominant symptom was anxiety in clinical presentations of neurosis, depression, drug-addiction or alcoholism, senile dementia or oligophrenia. The doses administered ranged from 6 to 12 mg/day and in some cases from 18 to 36 mg/day. Distinct improvement was noted in 20 patients, the effects of the drug on anxiety being manifested within 2 to 3 days. The somatic symptoms of anxiety and sleep disturbances were also improved. However, depressive and psychotic symptoms remained unchanged and it was necessary to combine diazepam with other drugs. Side-effects consisted of daytime somnolence in 2 cases and feeling of dizziness in 3 cases.
 ...
PMID:[The action of bromazepam on anxiety (author's transl)]. 612 47


1 2 3 4 5 6 Next >>